"Expanding Portfolio in Respiratory and Anti-Infective Treatments"

Daewoong Bio announced on July 2 that it has signed a co-promotion agreement with Youngjin Pharm for two prescription drugs, expanding its portfolio into the respiratory and anti-infective treatment sectors.


Exterior view of Daewoong Bio factory. Daewoong Bio

Exterior view of Daewoong Bio factory. Daewoong Bio

View original image

Under this agreement, starting this month, Daewoong Bio will jointly promote Youngjin Pharm's "Pulmecool Nebulizer Suspension" (active ingredient: budesonide) and "Linezolin" (active ingredient: linezolid). Youngjin Pharm will ensure a stable supply of the two products based on its product development and supply capabilities, while Daewoong Bio will focus on establishing the products in the market by leveraging its prescription drug sales and marketing expertise.



Daewoong Bio stated, "We plan to strengthen our corporate competitiveness by expanding our product portfolio from a focus on central nervous system (CNS) drugs to include respiratory and anti-infective areas."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing